Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CYTK, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA | Options-implied move |
|---|---|---|---|---|---|
| 2026-11-14 | — | adults with symptomatic oHCM to improve functional capacity | sNDA | 86% | ±17% by Nov 20 |
Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Oct 2). It prices every move until that expiry, not only the FDA decision.
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area and cash runway. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Aficamten FDA approved Dec 2025 · Myqorzo |
Hypertrophic Cardiomyopathy (HCM) | Phase 4 · NCT07600177 | Recruiting |
| Tirasemtiv | Amyotrophic Lateral Sclerosis (ALS) | Phase 3 · NCT02936635 | Completed |
| Omecamtiv Mecarbil | Heart Failure With Reduced Ejection Fraction | Phase 3 · NCT03759392 | Completed |
| Reldesemtiv | Amyotrophic Lateral Sclerosis | Phase 3 · NCT04944784 | Terminated |
| CK-3773274 | Hypertrophic Cardiomyopathy (HCM) | Phase 2 · NCT04219826 | Completed |
| Ulacamten | Symptomatic Heart Failure With Preserved Ejection | Phase 2 · NCT06793371 | Recruiting |
| Omecamtiv Mecarbil Matrix F1 Formulation | Modified Release Oral Formulation | Phase 2 · NCT01786512 | Completed |
| Omecamtiv Mecarbil Matrix F2 Formulation | Modified Release Oral Formulation | Phase 2 · NCT01786512 | Completed |
| Omecamtiv Mecarbil Swellable Core Techno | Modified Release Oral Formulation | Phase 2 · NCT01786512 | Completed |
| KSP Inhibitor SB-743921 | Non-Hodgkin's Lymphoma | Phase 1/2 · NCT00343564 | Completed |
| CK-1827452 | Heart Failure | Phase 2 · NCT00624442 | Completed |
| Moxifloxacin | QT Intervals Changes | Phase 1 · NCT04175808 | Completed |
| AMG 423 | Heart Failure | Phase 1 · NCT01737866 | Completed |
| Ispinesib | Breast Neoplasms | Phase 1 · NCT00607841 | Terminated |
| CK-3773274 - Granules in Capsule | Symptomatic Obstructive Hypertrophic Cardiomyopath | Phase 1 · NCT03767855 | Completed |
| CK-4021586 | Healthy Participants | Phase 1 · NCT05877053 | Completed |
Also used in these trials (approved or third-party drugs, not CYTK's own candidates): Metoprolol Succinate Er, Riluzole.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CYTK holds $1.7B in cash and short-term investments (as of Jun 30, 2026) and burns about $152.6M/quarter from operations, an estimated runway of 33.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 47 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CYTK files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 20,094,362 | 14.45% | 2026-06-30 |
| T. Rowe Price Investment Management, Inc | Institution (13G, 5%+) | 17,716,372 | 12.74% | 2025-12-31 |
| Wellington Management Group LLP | Institution (13G, 5%+) | 7,116,724 | 5.12% | 2026-06-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 6,711,799 | 4.83% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 6,494,233 | 4.67% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 6,422,042 | 4.62% | 2026-03-31 |
| FMR, LLC | Institution (13F) | 5,031,782 | 3.62% | 2026-06-30 |
| Avoro Capital Advisors LLC | Institution (13F) | 4,999,999 | 3.60% | 2026-06-30 |
| Bank of America Corporation | Institution (13F) | 4,635,709 | 3.33% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 3,712,501 | 2.67% | 2026-06-30 |
| Robert I Blum President & CEO, Director · +262,774 options |
Insider | 282,710 | 0.20% | 2026-09-28 |
| Fady Ibraham Malik EVP Research & Development · +64,578 options |
Insider | 153,902 | 0.11% | 2026-09-22 |
Share count 139,023,418 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-28 filed 2026-09-28 |
Blum Robert I |
Option exercise (M) | 7,500 | $10.60 | 286,044 |
| 2026-09-28 filed 2026-09-28 |
Blum Robert I |
Sale (S) | 7,500 | $65.46 | 278,544 |
| 2026-09-28 filed 2026-09-28 |
Blum Robert I |
Option exercise (M) | 7,500 | – | – |
| 2026-09-22 filed 2026-09-22 |
Malik Fady Ibraham |
Sale (S) | 3,500 | $68.29 | 153,902 |
| 2026-09-22 filed 2026-09-22 |
Malik Fady Ibraham |
Option exercise (M) | 3,500 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-12-26 | MYQORZO | NDA | -4.5% | -1.7% | -3.8% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CYTK and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →